Literature DB >> 23852543

The therapeutic potential of GPR43: a novel role in modulating metabolic health.

Lauren M Cornall1, Michael L Mathai, Deanne H Hryciw, Andrew J McAinch.   

Abstract

GPR43 is a receptor for short-chain fatty acids. Preliminary data suggest a putative role for GPR43 in regulating systemic health via processes including inflammation, carcinogenesis, gastrointestinal function, and adipogenesis. GPR43 is involved in secretion of gastrointestinal peptides, which regulate appetite and gastrointestinal motility. This suggests GPR43 may have a role in weight control. Moreover, GPR43 regulates plasma lipid profile and inflammatory processes, which further indicates that GPR43 could have the ability to modulate the etiology and pathogenesis of metabolic diseases such as obesity, type 2 diabetes mellitus, and cardiovascular disease. This review summarizes the current evidence regarding the ability of GPR43 to mediate both systemic and tissue specific functions and how GPR43 may be modulated in the treatment of metabolic disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23852543     DOI: 10.1007/s00018-013-1419-9

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  125 in total

1.  Body weight and weight gain during adult life in men in relation to coronary heart disease and mortality. A prospective population study.

Authors:  A Rosengren; H Wedel; L Wilhelmsen
Journal:  Eur Heart J       Date:  1999-02       Impact factor: 29.983

Review 2.  Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity.

Authors:  Jason C G Halford; Joanne A Harrold; Clare L Lawton; John E Blundell
Journal:  Curr Drug Targets       Date:  2005-03       Impact factor: 3.465

3.  Reduced insulin suppression of glucose appearance is related to susceptibility to dietary obesity in rats.

Authors:  M J Pagliassotti; T J Horton; E C Gayles; T A Koppenhafer; T D Rosenzweig; J O Hill
Journal:  Am J Physiol       Date:  1997-04

4.  Allosteric rescuing of loss-of-function FFAR2 mutations.

Authors:  Gayathri Swaminath; Peter Jaeckel; Qi Guo; Mario Cardozo; Jennifer Weiszmann; Richard Lindberg; Yingcai Wang; Ralf Schwandner; Yang Li
Journal:  FEBS Lett       Date:  2010-09-17       Impact factor: 4.124

5.  Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo.

Authors:  Ryosuke Nakano; Eiji Kurosaki; Shigeru Yoshida; Masanori Yokono; Akiyoshi Shimaya; Tatsuya Maruyama; Masayuki Shibasaki
Journal:  Biochem Pharmacol       Date:  2006-04-07       Impact factor: 5.858

6.  Short-chain fatty acid receptor, GPR43, is expressed by enteroendocrine cells and mucosal mast cells in rat intestine.

Authors:  Shin-ichiro Karaki; Retsu Mitsui; Hisayoshi Hayashi; Ikuo Kato; Hiroshi Sugiya; Toshihiko Iwanaga; John B Furness; Atsukazu Kuwahara
Journal:  Cell Tissue Res       Date:  2006-02-01       Impact factor: 5.249

Review 7.  Endocrine functions of adipose tissue: focus on adiponectin.

Authors:  James R Sowers
Journal:  Clin Cornerstone       Date:  2008

8.  PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet.

Authors:  Anita M van den Hoek; Annemieke C Heijboer; Eleonora P M Corssmit; Peter J Voshol; Johannes A Romijn; Louis M Havekes; Hanno Pijl
Journal:  Diabetes       Date:  2004-08       Impact factor: 9.461

Review 9.  Regulation of inflammation by short chain fatty acids.

Authors:  Marco A R Vinolo; Hosana G Rodrigues; Renato T Nachbar; Rui Curi
Journal:  Nutrients       Date:  2011-10-14       Impact factor: 5.717

10.  Blunting of AICAR-induced human skeletal muscle glucose uptake in type 2 diabetes is dependent on age rather than diabetic status.

Authors:  John Andree Babraj; Kristy Mustard; Calum Sutherland; Mhari C Towler; Shaui Chen; Kenneth Smith; Kevin Green; Graham Leese; David Grahame Hardie; Michael J Rennie; Daniel James Cuthbertson
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-02-03       Impact factor: 4.310

View more
  4 in total

Review 1.  Benefits of short-chain fatty acids and their receptors in inflammation and carcinogenesis.

Authors:  Sathish Sivaprakasam; Puttur D Prasad; Nagendra Singh
Journal:  Pharmacol Ther       Date:  2016-04-23       Impact factor: 12.310

2.  GPR43 activation-mediated lipotoxicity contributes to podocyte injury in diabetic nephropathy by modulating the ERK/EGR1 pathway.

Authors:  Jian Lu; Pei Pei Chen; Jia Xiu Zhang; Xue Qi Li; Gui Hua Wang; Ben Yin Yuan; Si Jia Huang; Xiao Qi Liu; Ting Ting Jiang; Meng Ying Wang; Wen Tao Liu; Xiong Zhong Ruan; Bi Cheng Liu; Kun Ling Ma
Journal:  Int J Biol Sci       Date:  2022-01-01       Impact factor: 6.580

Review 3.  Treatment of type 2 diabetes by free Fatty Acid receptor agonists.

Authors:  Kenneth R Watterson; Brian D Hudson; Trond Ulven; Graeme Milligan
Journal:  Front Endocrinol (Lausanne)       Date:  2014-08-28       Impact factor: 5.555

4.  Central Agonism of GPR120 Acutely Inhibits Food Intake and Food Reward and Chronically Suppresses Anxiety-Like Behavior in Mice.

Authors:  Stéphanie Auguste; Alexandre Fisette; Maria F Fernandes; Cécile Hryhorczuk; Vincent Poitout; Thierry Alquier; Stephanie Fulton
Journal:  Int J Neuropsychopharmacol       Date:  2016-07-05       Impact factor: 5.176

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.